CORRESPONDENCE: LETTER TO THE EDITOR
Reply
Jonathan R. Nebeker, MS, MD*,
Renu Virmani, MD,
Charles L. Bennett, MD, PhD, MPP and
Marc D. Feldman, MD, FACC
* VA Salt Lake City Health Care System, 500 Foothill Boulevard, Salt Lake City, Utah 84148 (Email: jonathan.nebeker{at}hsc.utah.edu).
We appreciate the letter by Dr. Kounis and colleagues that expands upon our discussion of the literature on stent-associated hypersensitivity (1). In conjunction with the RADAR (Research on Adverse Drug events And Reports) project (2), we have started a protocol that incorporates some of the suggestions of Dr. Kounis and colleagues. This protocol includes skin tests to stent components and laboratory tests. It also features a methodical approach to dechallenge and rechallenge (3) for concomitant medication while maintaining antiplatelet coverage. To refer patients, please contact Dr. Marc Feldman, Associate Professor, Department of medicine, University of Texas, San Antonio (E-mail: feldmanm@uthscsa.edu).
 |
References
|
|---|
1. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stentsa review of available cases from the Research on Adverse Drug events And Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-181.[Abstract/Free Full Text]2. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug events And Reports (RADAR) project JAMA 2005;293:2131-2140.[Abstract/Free Full Text] 3. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug eventsa clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 2004;140:795-801.[Abstract/Free Full Text]
|
Top
References